PHARMAQ
Timeline
35 events since 2003Board
Filings
Financial
Establishments
Address
200420062008201020122014201620182020202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed PDFmicro format · 57 days before the deadline
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0479480106
Annual accounts 2024 filed PDFmicro format · 55 days before the deadline
2024
Annual accounts 2023 filed PDFmicro format · 54 days before the deadline
2023
Annual accounts 2022 filed PDFmicro format · 17 days late
Registered office moved within MonsNew registered office: Rue Charles Piron, 66 à 7011 Mons (Ghlin) · Previous registered office: Rue A. Brohée, 30-7011 MONS (GHLIN) · Resignations: FONTAINE Nathalie (managing director) and BLANCHARD Hervé (director) · General meeting of 19-12-20227 points ▸
- General meeting, 19-12-2022
- Director resignation, FONTAINE Nathalie (managing director)
- Director resignation, BLANCHARD Hervé
- Director appointment, DE BROUX Anne-Laure (managing director)
- Registered-office move, Rue Charles Piron, 66 à 7011 Mons (Ghlin)
- Director discharge, FONTAINE Nathalie
- Director discharge, BLANCHARD Hervé
2022
Back to profit net €54,912 The net result is €54,912, after one loss-making year.
Liquidity more than triples current ratio 2.49 The current ratio rises from 0.81 to 2.49. Short-term debt falls from €200,153 to €78,061.
Annual accounts 2021 filed PDFmicro format · 31 days late
Reappointments: FONTAINE Nathalie (managing director) and BLANCHARD Hervé (director and chair of the board)General meeting of 04-06-20213 points ▸
- General meeting, 04-06-2021
- Director reappointment, FONTAINE Nathalie (managing director)
- Director reappointment, BLANCHARD Hervé (director and chair of the board)
2021
Annual accounts 2020 filed PDFmicro format · 30 days late
2020
Annual accounts 2019 filed PDFmicro format · 30 days late
2019
Back to profit net €1,990 The net result is €1,990, after 6 loss-making years.
Annual accounts 2018 filed PDFmicro format · 14 days before the deadline
2018
Annual accounts 2017 filed PDFmicro format · 30 days late
Reappointments: FONTAINE Nathalie (managing director) and BLANCHARD Hervé (director and chair of the board)General meeting of 04-06-20153 points ▸
- General meeting, 04-06-2015
- Director reappointment, FONTAINE Nathalie (managing director)
- Director reappointment, BLANCHARD Hervé (director and chair of the board)
2017
Annual accounts 2016 filed PDFfull format · 29 days late
2016
Annual accounts 2015 filed PDFfull format · 24 days late
2015
Annual accounts 2014 filed PDFfull format · 27 days late
2014
Weakest financial year net -€100,717 The net result drops to -€100,717, the lowest from 2006 to 2025. It recovers the following year.
Annual accounts 2013 filed PDFfull format · 61 days late
2013
Annual accounts 2012 filed PDFfull format · 55 days late
2012
Annual accounts 2011 filed PDFfull format · 92 days late
2011
Annual accounts 2010 filed PDFfull format · 9 days before the deadline
2010
Equity above €200,000 equity €221,589 ▲17.9% With a profit in every financial year since 2006, equity grows to €221,589.
Annual accounts 2009 filed PDFfull format · 52 days late
2009
Annual accounts 2008 filed PDFfull format · 60 days late
2008
Equity above €150,000 equity €157,157 ▲10.4% With a profit in every financial year since 2006, equity grows to €157,157.
Annual accounts 2007 filed PDFfull format · 53 days late
2007
Annual accounts 2006 filed PDFfull format · 21 days before the deadline
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
PHARMAQ was incorporated on 22 January 2003.1 The registered office was moved to Mons in 2023.2 Since 2023, DE BROUX Anne-Laure has served as managing director.3 Total assets rose from €201,734 in 2018 to €375,271 in 2025 and headcount from 1.7 to 1.3 full-time equivalents.4